INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer

Stock Information for Inhibitor Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibitor Therapeutics Inc

Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA
INHIBITOR Therapeutics Appoints Dr. Debra Peattie to its Board of Directors
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.